

# Joe Y Chang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6431889/publications.pdf>

Version: 2024-02-01

222  
papers

14,345  
citations

22548

61  
h-index

26792

111  
g-index

265  
all docs

265  
docs citations

265  
times ranked

11229  
citing authors

#	ARTICLE	IF	CITATIONS
1	Monte Carlo evaluation of target dose coverage in lung stereotactic body radiation therapy with flattening filter-free beams. <i>Journal of Radiotherapy in Practice</i> , 2022, 21, 81-87.	0.2	1
2	American Radium Society Appropriate Use Criteria for Radiation Therapy in Oligometastatic or Oligoprogressive Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 112, 361-375.	0.4	22
3	An algorithm for thoracic re-irradiation using biologically effective dose: a common language on how to treat in a "no-treat zone" <i>Radiation Oncology</i> , 2022, 17, 4.	1.2	1
4	Immunotherapy for the Neoadjuvant Management of Resectable Intrathoracic Cancers. <i>JAMA Oncology</i> , 2022, 8, 333.	3.4	2
5	AAPM Task Group Report 290: Respiratory motion management for particle therapy. <i>Medical Physics</i> , 2022, 49, .	1.6	30
6	Local Consolidative Therapy Versus Systemic Therapy Alone for Metastatic Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 635-644.	0.4	18
7	Radiotherapy plus immune checkpoint blockade in PD(L)-1-resistant metastatic NSCLC. <i>Lancet Oncology</i> , The, 2022, 23, e156.	5.1	9
8	Clinical necessity of multi-image based (4DMIB) optimization for targets affected by respiratory motion and treated with scanned particle therapy " A comprehensive review. <i>Radiotherapy and Oncology</i> , 2022, 169, 77-85.	0.3	12
9	Quantifying the rate and predictors of occult lymph node involvement in patients with clinically node-negative non-small cell lung cancer. <i>Acta OncolÃ³gica</i> , 2022, 61, 403-408.	0.8	6
10	Optimize Local Therapy for Oligometastatic and Oligoprogressive Non-Small Cell Lung Cancer to Enhance Survival. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2022, 20, 531-539.	2.3	10
11	Predictive performance of different NTCP techniques for radiation-induced esophagitis in NSCLC patients receiving proton radiotherapy. <i>Scientific Reports</i> , 2022, 12, .	1.6	4
12	Alleviating breathlessness in patients with cancer with dexamethasone (ABCD): A parallel-group, double-blind, randomized clinical trial (RCT).. <i>Journal of Clinical Oncology</i> , 2022, 40, 12112-12112.	0.8	0
13	Using FFF beams to improve the therapeutic ratio of lung SBRT. <i>Journal of Radiotherapy in Practice</i> , 2021, 20, 419-425.	0.2	5
14	Use of Multi-Site Radiation Therapy for Systemic Disease Control. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 109, 352-364.	0.4	34
15	Postoperative Radiotherapy for Locally Advanced NSCLC: Implications for Shifting to Conformal, High-Risk Fields. <i>Clinical Lung Cancer</i> , 2021, 22, 225-233.e7.	1.1	2
16	American Radium Society Appropriate Use Criteria on Radiation Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 54-65.	0.5	13
17	Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Respiratory Medicine</i> , the, 2021, 9, 467-475.	5.2	277
18	When Constrained by Constraints: Thinking Outside of the Box in Both Technology and Biology. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 110, 266-267.	0.4	5

#	ARTICLE	IF	CITATIONS
19	Toxicity and Survival After Intensity-Modulated Proton Therapy Versus Passive Scattering Proton Therapy for NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 269-277.	0.5	23
20	American Radium Society Appropriate Use Criteria: Radiation Therapy for Limited-Stage SCLC 2020. <i>Journal of Thoracic Oncology</i> , 2021, 16, 66-75.	0.5	17
21	Could the clinical target volume be omitted for radiotherapy of locally advanced non-small cell lung cancer in the modern era?. <i>Translational Lung Cancer Research</i> , 2021, 10, 5-8.	1.3	1
22	Effects of glutamine for prevention of radiation-induced esophagitis: a double-blind placebo-controlled trial. <i>Investigational New Drugs</i> , 2021, 39, 1113-1122.	1.2	3
23	Consensus Statement on Proton Therapy in Mesothelioma. <i>Practical Radiation Oncology</i> , 2021, 11, 119-133.	1.1	11
24	Prognosis of severe lymphopenia after postoperative radiotherapy in non-small cell lung cancer: Results of a long-term follow up study. <i>Clinical and Translational Radiation Oncology</i> , 2021, 28, 54-61.	0.9	5
25	Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial.. <i>Journal of Clinical Oncology</i> , 2021, 39, 8506-8506.	0.8	7
26	Early and Midtreatment Mortality in Palliative Radiotherapy: Emphasizing Patient Selection in High-Quality End-of-Life Care. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2021, 19, 805-813.	2.3	2
27	Considerations for Clinical Trials Testing Radiotherapy Combined With Immunotherapy for Metastatic Disease. <i>Seminars in Radiation Oncology</i> , 2021, 31, 217-226.	1.0	2
28	Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II/III Non-Small Cell Lung Cancer and Poor Performance Status. <i>JAMA Oncology</i> , 2021, 7, 1497.	3.4	45
29	High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial. <i>Radiotherapy and Oncology</i> , 2021, 162, 60-67.	0.3	45
30	Single Institution Experience of Proton and Photon-based Postoperative Radiation Therapy for Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2021, 22, e745-e755.	1.1	15
31	Stereotactic ablative radiotherapy for operable stage I non-small-cell lung cancer (revised STARS): long-term results of a single-arm, prospective trial with prespecified comparison to surgery. <i>Lancet Oncology</i> , 2021, 22, 1448-1457.	5.1	154
32	Increased biologically effective dose (BED) to the primary tumor is associated with improved survival in patients with oligometastatic NSCLC. <i>Radiotherapy and Oncology</i> , 2021, 163, 114-118.	0.3	12
33	Executive Summary of Clinical and Technical Guidelines for Esophageal Cancer Proton Beam Therapy From the Particle Therapy Co-Operative Group Thoracic and Gastrointestinal Subcommittees. <i>Frontiers in Oncology</i> , 2021, 11, 748331.	1.3	4
34	SABR for operable stage I non-small-cell lung cancer: comparison to surgery – Authors' reply. <i>Lancet Oncology</i> , 2021, 22, e537-e538.	5.1	0
35	Phase I Trial of Pembrolizumab and Radiation Therapy after Induction Chemotherapy for Extensive-Stage Small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2020, 15, 266-273.	0.5	58
36	Predicting 5-Year Progression and Survival Outcomes for Early Stage Non-small Cell Lung Cancer Treated with Stereotactic Ablative Radiation Therapy: Development and Validation of Robust Prognostic Nomograms. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 90-99.	0.4	24

#	ARTICLE	IF	CITATIONS
37	Biologically Effective Dose in Stereotactic Body Radiotherapy and Survival for Patients With Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 101-109.	0.5	38
38	Salvage Therapy for Locoregional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 176-189.	0.5	29
39	Minocycline Reduces Chemoradiation-Related Symptom Burden in Patients with Non-Small Cell Lung Cancer: A Phase 2 Randomized Trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 106, 100-107.	0.4	15
40	Commercial Insurance Coverage of Advanced Radiation Therapy Techniques Compared With American Society for Radiation Oncology Model Policies. <i>Practical Radiation Oncology</i> , 2020, 10, 324-329.	1.1	11
41	Phase II Trial of Concurrent Atezolizumab With Chemoradiation for Unresectable NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 248-257.	0.5	97
42	Phase 1/2 Trial of Pembrolizumab and Concurrent Chemoradiation Therapy for Limited-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1919-1927.	0.5	53
43	Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial. , 2020, 8, e001001.		143
44	American Radium Society (ARS) and American College of Radiology (ACR) Appropriate Use Criteria Systematic Review and Guidelines on Reirradiation for Non-small Cell Lung Cancer (NSCLC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E48-E49.	0.4	9
45	Metabolic Responses to Metformin in Inoperable Early-stage Non-“Small Cell Lung Cancer Treated With Stereotactic Radiotherapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2020, 43, 231-235.	0.6	17
46	Clinical and Radiographic Presentations of COVID-19 Among Patients Receiving Radiation Therapy for Thoracic Malignancies. <i>Advances in Radiation Oncology</i> , 2020, 5, 700-704.	0.6	9
47	Proton Reirradiation: Expert Recommendations for Reducing Toxicities and Offering New Chances of Cure in Patients With Challenging Recurrence Malignancies. <i>Seminars in Radiation Oncology</i> , 2020, 30, 253-261.	1.0	18
48	Randomized Phase IIb Trial of Proton Beam Therapy Versus Intensity-Modulated Radiation Therapy for Locally Advanced Esophageal Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 1569-1579.	0.8	158
49	Tyrosine Kinase Inhibitor Resistance Increased the Risk of Cerebral Radiation Necrosis After Stereotactic Radiosurgery in Brain Metastases of Non-small-Cell Lung Cancer: A Multi-Institutional Retrospective Case-Control Study. <i>Frontiers in Oncology</i> , 2020, 10, 12.	1.3	11
50	Outcomes and toxicities following stereotactic ablative radiotherapy for pulmonary metastases in patients with primary head and neck cancer. <i>Head and Neck</i> , 2020, 42, 1939-1953.	0.9	29
51	Thoracic Radiation Oncology Clinical Trial Accrual and Reasons for Nonenrollment: Results of a Large, Prospective, Multiyear Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 897-908.	0.4	2
52	An improved method for analyzing and reporting patterns of in-field recurrence after stereotactic ablative radiotherapy in early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2020, 145, 209-214.	0.3	3
53	Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 107, 261-269.	0.4	5
54	Association of Medicaid Insurance With Survival Among Patients With Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2020, 3, e203277.	2.8	15

#	ARTICLE	IF	CITATIONS
55	Rapid Detection of Asymptomatic Coronavirus Disease 2019 by Computed Tomography Image Guidance for Stereotactic Ablative Radiotherapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1085-1087.	0.5	15
56	Lymanâ€“Kutcherâ€“Burman normal tissue complication probability modeling for radiation-induced esophagitis in non-small cell lung cancer patients receiving proton radiotherapy. <i>Radiotherapy and Oncology</i> , 2020, 146, 200-204.	0.3	12
57	Does Pathologic Response Equate to Clinical Response Following SABR for Early-Stage NSCLC?. <i>Frontiers in Oncology</i> , 2019, 9, 551.	1.3	3
58	Proton therapy for non-small cell lung cancer: the road ahead. <i>Translational Lung Cancer Research</i> , 2019, 8, S202-S212.	1.3	15
59	Treatment modes for EGFR mutations in patients with brain metastases from non-small cell lung cancer: controversy, causes, and solutions. <i>Translational Lung Cancer Research</i> , 2019, 8, 524-531.	1.3	9
60	Results of a Phase 1/2 Trial of Chemoradiotherapy With Simultaneous Integrated Boost of Radiotherapy Dose in Unresectable Locally Advanced Esophageal Cancer. <i>JAMA Oncology</i> , 2019, 5, 1597.	3.4	53
61	Impact of Corticosteroid Administration on Outcomes Following Stereotactic Ablative Radiotherapy for Nonâ€“small-cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, e480-e488.	1.1	2
62	Bevacizumab treatment for radiation brain necrosis: mechanism, efficacy and issues. <i>Molecular Cancer</i> , 2019, 18, 21.	7.9	104
63	Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. <i>Frontiers in Immunology</i> , 2019, 10, 193.	2.2	105
64	Racial and Insurance-related Disparities in Delivery of Immunotherapy-type Compounds in the United States. <i>Journal of Immunotherapy</i> , 2019, 42, 55-64.	1.2	34
65	Phase II Trial of Ipilimumab with Stereotactic Radiation Therapy for Metastatic Disease: Outcomes, Toxicities, and Low-Dose Radiationâ€“Related Abscopal Responses. <i>Cancer Immunology Research</i> , 2019, 7, 1903-1909.	1.6	86
66	Time to abandon single-site irradiation for inducing abscopal effects. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 123-135.	12.5	233
67	Development of an Immune-Pathology Informed Radiomics Model for Non-Small Cell Lung Cancer. <i>Scientific Reports</i> , 2018, 8, 1922.	1.6	108
68	Development and Validation of a Predictive Radiomics Model for Clinical Outcomes in Stage I Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 1090-1097.	0.4	56
69	Implications for high-precision dose radiation therapy planning or limited surgical resection after percutaneous computed tomography-guided lung nodule biopsy using a tract sealant. <i>Advances in Radiation Oncology</i> , 2018, 3, 139-145.	0.6	2
70	Phase 2 Study of Stereotactic Body Radiation Therapy and Stereotactic Body Proton Therapy for High-Risk, Medically Inoperable, Early-Stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 558-563.	0.4	55
71	Impact of Spot Size and Spacing on the Quality of Robustly Optimized Intensity Modulated Proton Therapy Plans for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 479-489.	0.4	44
72	Reirradiation of thoracic cancers with intensity modulated proton therapy. <i>Practical Radiation Oncology</i> , 2018, 8, 58-65.	1.1	34

#	ARTICLE	IF	CITATIONS
73	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2018, 10, 21-24.	0.6	1
74	Combining radiation plus immunotherapy to improve systemic immune response. <i>Journal of Thoracic Disease</i> , 2018, 10, S468-S479.	0.6	46
75	Controversies in dose-escalation for locally advanced non-small cell lung cancer and the role of proton beam therapy. <i>Journal of Thoracic Disease</i> , 2018, 10, S1124-S1126.	0.6	4
76	Proton therapy for early-stage non-small cell lung cancer (NSCLC). <i>Translational Lung Cancer Research</i> , 2018, 7, 199-204.	1.3	8
77	How to optimize the treatment strategy for patients with EGFR-mutant stage IA lung adenocarcinoma: an international multidisciplinary team. <i>Journal of Thoracic Disease</i> , 2018, 10, 3883-3890.	0.6	2
78	Dose-escalation of locally advanced non-small cell lung cancer with proton beam therapy. <i>Translational Lung Cancer Research</i> , 2018, 7, S280-S282.	1.3	3
79	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. , 2018, 6, 128.		233
80	Association of Long-term Outcomes and Survival With Multidisciplinary Salvage Treatment for Local and Regional Recurrence After Stereotactic Ablative Radiotherapy for Early-Stage Lung Cancer. <i>JAMA Network Open</i> , 2018, 1, e181390.	2.8	48
81	Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. <i>Clinical Cancer Research</i> , 2018, 24, 5735-5743.	3.2	48
82	In Reply to Hurmuz and Ozyigit. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 101, 745.	0.4	0
83	Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients. <i>Journal of Cancer</i> , 2018, 9, 584-593.	1.2	29
84	Accounting for, Mitigating, and Choice of Margins for Moving Tumors. <i>Seminars in Radiation Oncology</i> , 2018, 28, 194-200.	1.0	4
85	Phase II randomized clinical trial comparing immunotherapy plus stereotactic ablative radiotherapy (I-SABR) versus SABR alone for stage I, selected stage IIa or isolated lung parenchymal recurrent non-small cell lung cancer: I-SABR. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS8580-TPS8580.	0.8	4
86	Trends and Outcomes of Proton Radiation Therapy Use for Non-Small Cell Lung Cancer. <i>International Journal of Particle Therapy</i> , 2018, 5, 18-27.	0.9	2
87	Long-term outcome of phase I/II prospective study of dose-escalated proton therapy for early-stage non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2017, 122, 274-280.	0.3	38
88	Long-Term Outcomes of Salvage Stereotactic Ablative Radiotherapy for Isolated Lung Recurrence of Non-Small Cell Lung Cancer: A Phase II Clinical Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 983-992.	0.5	51
89	7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial. <i>Cancer</i> , 2017, 123, 3031-3039.	2.0	125
90	Stereotactic Ablative Radiation Therapy is Highly Safe and Effective for Elderly Patients With Early-stage Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 98, 900-907.	0.4	37

#	ARTICLE	IF	CITATIONS
91	Endobronchial Ultrasound-Guided Transbronchial Needle Aspiration in the Nodal Staging of Stereotactic Ablative Body Radiotherapy Patients. <i>Annals of Thoracic Surgery</i> , 2017, 103, 1600-1605.	0.7	37
92	Patterns and correlates of treatment failure in relation to isodose distribution in non-small cell lung cancer: An analysis of 1522 patients in the modern era. <i>Radiotherapy and Oncology</i> , 2017, 125, 325-330.	0.3	0
93	Proton Beam Radiotherapy and Concurrent Chemotherapy for Unresectable Stage III Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2017, 3, e172032.	3.4	119
94	Comparative Outcomes After Definitive Chemoradiotherapy Using Proton Beam Therapy Versus Intensity Modulated Radiation Therapy for Esophageal Cancer: A Retrospective, Single-Institutional Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 667-676.	0.4	79
95	Consensus Guidelines for Implementing Pencil-Beam Scanning Proton Therapy for Thoracic Malignancies on Behalf of the PTCOG Thoracic and Lymphoma Subcommittee. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 41-50.	0.4	162
96	Local Control and Toxicity of a Simultaneous Integrated Boost for Dose Escalation in Locally Advanced Esophageal Cancer: Interim Results from a Prospective Phase I/II Trial. <i>Journal of Thoracic Oncology</i> , 2017, 12, 375-382.	0.5	58
97	Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. <i>Cancer Research</i> , 2017, 77, 839-850.	0.4	195
98	Ipilimumab with Stereotactic Ablative Radiation Therapy: Phase I Results and Immunologic Correlates from Peripheral T Cells. <i>Clinical Cancer Research</i> , 2017, 23, 1388-1396.	3.2	261
99	Stereotactic ablative radiotherapy for adrenal gland metastases: Factors influencing outcomes, patterns of failure, and dosimetric thresholds for toxicity. <i>Practical Radiation Oncology</i> , 2017, 7, e195-e203.	1.1	44
100	Incidence and predictors of chest wall toxicity after high-dose radiation therapy in 15 fractions. <i>Practical Radiation Oncology</i> , 2017, 7, 63-71.	1.1	8
101	Optimal sequencing of postoperative radiotherapy and chemotherapy in IIIA-N2 non-small cell lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 1394-1397.	0.6	3
102	PD-L1 expression in lung cancer. <i>Journal of Thoracic Disease</i> , 2016, 8, 3053-3055.	0.6	2
103	Is surgery still the optimal treatment for stage I non-small cell lung cancer?. <i>Translational Lung Cancer Research</i> , 2016, 5, 183-189.	1.3	22
104	Association between Genetic Variants in DNA Double-Strand Break Repair Pathways and Risk of Radiation Therapy-Induced Pneumonitis and Esophagitis in Non-Small Cell Lung Cancer. <i>Cancers</i> , 2016, 8, 23.	1.7	13
105	MiRNA-Related Genetic Variations Associated with Radiotherapy-Induced Toxicities in Patients with Locally Advanced Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2016, 11, e0150467.	1.1	7
106	A study on the evaluation method and recent clinical efficacy of bevacizumab on the treatment of radiation cerebral necrosis. <i>Scientific Reports</i> , 2016, 6, 24364.	1.6	29
107	Motion-robust intensity-modulated proton therapy for distal esophageal cancer. <i>Medical Physics</i> , 2016, 43, 1111-1118.	1.6	63
108	Prospective Study of Patient-Reported Symptom Burden in Patients With Non-Small-Cell Lung Cancer Undergoing Proton or Photon Chemoradiation Therapy. <i>Journal of Pain and Symptom Management</i> , 2016, 51, 832-838.	0.6	27

#	ARTICLE	IF	CITATIONS
109	Planning Target Volume D95 and Mean Dose Should Be Considered for Optimal Local Control for Stereotactic Ablative Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1226-1235.	0.4	56
110	Stereotactic Ablative Radiation Therapy Combined With Immunotherapy for Solid Tumors. <i>Cancer Journal (Sudbury, Mass)</i> , 2016, 22, 257-266.	1.0	38
111	Consensus Statement on Proton Therapy in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 505-516.	0.4	125
112	Stereotactic radiotherapy or surgery for early-stage non-small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2016, 17, e42-e43.	5.1	2
113	Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?. <i>Nature Reviews Clinical Oncology</i> , 2016, 13, 516-524.	12.5	288
114	Exploratory Study of 4D versus 3D Robust Optimization in Intensity Modulated Proton Therapy for Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 523-533.	0.4	103
115	Novel Hybrid Scattering- and Scanning-Beam Proton Therapy Approach. <i>International Journal of Particle Therapy</i> , 2016, 3, 37-50.	0.9	2
116	MTOR inhibition reversed drug resistance after combination radiation with erlotinib in lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 84688-84694.	0.8	12
117	Analysis of risk and predictors of brain radiation necrosis after radiosurgery. <i>Oncotarget</i> , 2016, 7, 7773-7779.	0.8	27
118	Acquired-resistance of bevacizumab treatment for radiation brain necrosis: a case report. <i>Oncotarget</i> , 2016, 7, 13265-13268.	0.8	7
119	Exploration of the recurrence in radiation brain necrosis after bevacizumab discontinuation. <i>Oncotarget</i> , 2016, 7, 48842-48849.	0.8	9
120	Stereotactic Ablative Radiotherapy for Centrally Located Early Stage Non-Small-Cell Lung Cancer: What We Have Learned. <i>Journal of Thoracic Oncology</i> , 2015, 10, 577-585.	0.5	133
121	Radiation with immunotherapy: an emerging combination for cancer treatment. <i>Journal of Radiation Oncology</i> , 2015, 4, 331-338.	0.7	5
122	The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. <i>Cancer Treatment Reviews</i> , 2015, 41, 503-510.	3.4	482
123	In Vivo Delivery of miR-34a Sensitizes Lung Tumors to Radiation Through RAD51 Regulation. <i>Molecular Therapy - Nucleic Acids</i> , 2015, 4, e270.	2.3	63
124	Use of Simultaneous Radiation Boost Achieves High Control Rates in Patients With Non-Small-Cell Lung Cancer Who Are Not Candidates for Surgery or Conventional Chemoradiation. <i>Clinical Lung Cancer</i> , 2015, 16, 156-163.	1.1	31
125	Robust optimization in intensity-modulated proton therapy to account for anatomy changes in lung cancer patients. <i>Radiotherapy and Oncology</i> , 2015, 114, 367-372.	0.3	72
126	Surgery versus SABR for resectable non-small-cell lung cancer – Authors' reply. <i>Lancet Oncology</i> , The, 2015, 16, e374-e375.	5.1	10



#	ARTICLE	IF	CITATIONS
127	Incidence and predictors of severe acute esophagitis and subsequent esophageal stricture in patients treated with accelerated hyperfractionated chemoradiation for limited-stage small cell lung cancer. <i>Practical Radiation Oncology</i> , 2015, 5, e383-e391.	1.1	22
128	Long-term outcomes after proton therapy, with concurrent chemotherapy, for stage II-III inoperable non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2015, 115, 367-372.	0.3	82
129	Intensity-Modulated Radiotherapy, Not 3 Dimensional Conformal, Is the Preferred Technique for Treating Locally Advanced Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2015, 25, 110-116.	1.0	32
130	Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. <i>Lancet Oncology</i> , The, 2015, 16, 630-637.	5.1	1,220
131	A Randomized Phase 2 Study Comparing 2 Stereotactic Body Radiation Therapy Schedules for Medically Inoperable Patients With Stage I Peripheral Non-Small Cell Lung Cancer: NRG Oncology RTOG 0915 (NCCTG N0927). <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 93, 757-764.	0.4	317
132	Strategies for combining immunotherapy with radiation for anticancer therapy. <i>Immunotherapy</i> , 2015, 7, 967-980.	1.0	83
133	Hemithoracic Intensity Modulated Radiation Therapy After Pleurectomy/Decortication for Malignant Pleural Mesothelioma: Toxicity, Patterns of Failure, and a Matched Survival Analysis. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 149-156.	0.4	52
134	Charged Particles in Stereotactic Radiosurgery. , 2015, , 135-146.		1
135	Stereotactic ablative radiotherapy: aim for a cure of cancer. <i>Annals of Translational Medicine</i> , 2015, 3, 12.	0.7	4
136	Progress of clinical research on targeted therapy combined with thoracic radiotherapy for non-small-cell lung cancer. <i>Drug Design, Development and Therapy</i> , 2014, 8, 667.	2.0	11
137	Lobectomy, Sublobar Resection, and Stereotactic Ablative Radiotherapy for Early-Stage Non-Small Cell Lung Cancers in the Elderly. <i>JAMA Surgery</i> , 2014, 149, 1244.	2.2	227
138	Proton-Based Stereotactic Ablative Radiotherapy in Early-Stage Non-Small-Cell Lung Cancer. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	10
139	Evaluation and mitigation of the interplay effects of intensity modulated proton therapy for lung cancer in a clinical setting. <i>Practical Radiation Oncology</i> , 2014, 4, e259-e268.	1.1	56
140	Stereotactic ablative radiotherapy (SABR) using 70Gy in 10 fractions for non-small cell lung cancer: Exploration of clinical indications. <i>Radiotherapy and Oncology</i> , 2014, 112, 256-261.	0.3	78
141	Clinical Implementation of Intensity Modulated Proton Therapy for Thoracic Malignancies. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 809-818.	0.4	125
142	Definitive Reirradiation for Locoregionally Recurrent Non-Small Cell Lung Cancer With Proton Beam Therapy or Intensity Modulated Radiation Therapy: Predictors of High-Grade Toxicity and Survival Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 819-827.	0.4	71
143	In Reply to Oskan. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 89, 1142.	0.4	0
144	On the interplay effects with proton scanning beams in stage III lung cancer. <i>Medical Physics</i> , 2014, 41, 021721.	1.6	87

#	ARTICLE	IF	CITATIONS
145	In Regard to Vanderstraeten et al. International Journal of Radiation Oncology Biology Physics, 2014, 90, 238.	0.4	2
146	Assessing the robustness of passive scattering proton therapy with regard to local recurrence in stage III non-small cell lung cancer: a secondary analysis of a phase II trial. Radiation Oncology, 2014, 9, 108.	1.2	10
147	Stereotactic Ablative Radiation Therapy for Centrally Located Early Stage or Isolated Parenchymal Recurrences of Non-Small Cell Lung Cancer: How to Fly in a "No Fly Zone". International Journal of Radiation Oncology Biology Physics, 2014, 88, 1120-1128.	0.4	225
148	Evaluation of the systematic error in using 3D dose calculation in scanning beam proton therapy for lung cancer. Journal of Applied Clinical Medical Physics, 2014, 15, 47-56.	0.8	11
149	Accelerated dose escalation with proton beam therapy for non-small cell lung cancer. Journal of Thoracic Disease, 2014, 6, 348-55.	0.6	7
150	Individualized hypo/hyperfractionated radiotherapy for non-small cell lung cancer. Journal of Thoracic Disease, 2014, 6, 285-6.	0.6	2
151	Cardiac 18F-fluorodeoxyglucose uptake on positron emission tomography after thoracic stereotactic body radiation therapy. Radiotherapy and Oncology, 2013, 109, 82-88.	0.3	42
152	Evaluating proton stereotactic body radiotherapy to reduce chest wall dose in the treatment of lung cancer. Medical Dosimetry, 2013, 38, 442-447.	0.4	19
153	Can Stereotactic Ablative Radiotherapy in Early Stage Lung Cancers Produce Comparable Success as Surgery?. Thoracic Surgery Clinics, 2013, 23, 369-381.	0.4	18
154	Clinical Controversies: Proton Therapy for Thoracic Tumors. Seminars in Radiation Oncology, 2013, 23, 115-119.	1.0	17
155	New weighted maximum intensity projection images from cine CT for delineation of the lung tumor plus motion. Medical Physics, 2013, 40, 061901.	1.6	5
156	Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: Predictors of use and association with toxicities. Lung Cancer, 2013, 82, 252-259.	0.9	61
157	Feasibility of proton beam therapy for reirradiation of locoregionally recurrent non-small cell lung cancer. Radiotherapy and Oncology, 2013, 109, 38-44.	0.3	66
158	Oncology Scan "Promising Strategies for the Treatment of Locally-Advanced Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 1-4.	0.4	14
159	Comparison of 2 Common Radiation Therapy Techniques for Definitive Treatment of Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 87, 139-147.	0.4	36
160	Stereotactic ablative radiotherapy: A potentially curable approach to early stage multiple primary lung cancer. Cancer, 2013, 119, 3402-3410.	2.0	75
161	Phase 1 Study of Dose Escalation in Hypofractionated Proton Beam Therapy for Non-Small Cell Lung Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 86, 665-670.	0.4	51
162	Evolution of modern-era radiotherapy strategies for unresectable advanced non-small-cell lung cancer. Lung Cancer Management, 2013, 2, 213-225.	1.5	2

#	ARTICLE	IF	CITATIONS
163	Therapy-Resistant Cancer Stem Cells Have Differing Sensitivity to Photon versus Proton Beam Radiation. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1484-1491.	0.5	55
164	Capsular contracture of subcutaneous breast implant following hypofractionated stereotactic body radiotherapy for early stage lung cancer. <i>Journal of Radiosurgery and SBRT</i> , 2013, 2, 165-170.	0.2	0
165	Primary Lung Cancer. <i>Medical Radiology</i> , 2012, , 137-162.	0.0	2
166	Positron Emission Tomography/Computed Tomography-Guided Intensity-Modulated Radiotherapy for Limited-Stage Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 82, e91-e97.	0.4	62
167	Positron Emission Tomography for Assessing Local Failure After Stereotactic Body Radiotherapy for Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 83, 1558-1565.	0.4	86
168	Automated Volumetric Modulated Arc Therapy Treatment Planning for Stage III Lung Cancer: How Does It Compare With Intensity-Modulated Radio Therapy?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, e69-e76.	0.4	48
169	Predicting Radiation Pneumonitis After Stereotactic Ablative Radiation Therapy in Patients Previously Treated With Conventional Thoracic Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1017-1023.	0.4	87
170	Adaptive/Nonadaptive Proton Radiation Planning and Outcomes in a Phase II Trial for Locally Advanced Non-small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1093-1100.	0.4	70
171	Comparative Effectiveness of 5 Treatment Strategies for Early-Stage Non-Small Cell Lung Cancer in the Elderly. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012, 84, 1060-1070.	0.4	246
172	Improving cardiac dosimetry: Alternative beam arrangements for intensity modulated radiation therapy planning in patients with carcinoma of the distal esophagus. <i>Practical Radiation Oncology</i> , 2012, 2, 41-45.	1.1	11
173	Coxsackie-adenovirus receptor as a novel marker of stem cells in treatment-resistant non-small cell lung cancer. <i>Radiotherapy and Oncology</i> , 2012, 105, 250-257.	0.3	15
174	Clinical outcome and predictors of survival and pneumonitis after stereotactic ablative radiotherapy for stage I non-small cell lung cancer. <i>Radiation Oncology</i> , 2012, 7, 152.	1.2	124
175	FDG uptake correlates with recurrence and survival after treatment of unresectable stage III non-small cell lung cancer with high-dose proton therapy and chemotherapy. <i>Radiation Oncology</i> , 2012, 7, 144.	1.2	22
176	Proton therapy for non-small cell lung cancer: Current evidence and future directions. <i>Thoracic Cancer</i> , 2012, 3, 99-108.	0.8	2
177	Stereotactic ablative radiotherapy: what's in a name?. <i>Practical Radiation Oncology</i> , 2011, 1, 38-39.	1.1	53
178	Cancer Stem Cell Radioresistance and Enrichment: Where Frontline Radiation Therapy May Fail in Lung and Esophageal Cancers. <i>Cancers</i> , 2011, 3, 1232-1252.	1.7	52
179	Proton therapy in clinical practice. <i>Chinese Journal of Cancer</i> , 2011, 30, 315-326.	4.9	56
180	Adaptive Radiation for Lung Cancer. <i>Journal of Oncology</i> , 2011, 2011, 1-10.	0.6	28

#	ARTICLE	IF	CITATIONS
181	Early findings on toxicity of proton beam therapy with concurrent chemotherapy for nonsmall cell lung cancer. <i>Cancer</i> , 2011, 117, 3004-3013.	2.0	117
182	Phase 2 study of high-dose proton therapy with concurrent chemotherapy for unresectable stage III nonsmall cell lung cancer. <i>Cancer</i> , 2011, 117, 4707-4713.	2.0	157
183	Proton Stereotactic Body Radiation Therapy for Clinically Challenging Cases of Centrally and Superiorly Located Stage I Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1015-1022.	0.4	117
184	Obesity Increases the Risk of Chest Wall Pain From Thoracic Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 81, 91-96.	0.4	92
185	Toxicity and Patterns of Failure of Adaptive/Ablative Proton Therapy for Early-Stage, Medically Inoperable Non-Small Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 1350-1357.	0.4	82
186	Implementation of Feedback-Guided Voluntary Breath-Hold Gating for Cone Beam CT-Based Stereotactic Body Radiotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2011, 80, 909-917.	0.4	50
187	Scalpel or SABR for Treatment of Early-Stage Lung Cancer: Clinical Considerations for the Multidisciplinary Team. <i>Cancers</i> , 2011, 3, 3432-3448.	1.7	2
188	Stereotactic ablative radiotherapy for stage I NSCLC: Successes and existing challenges. <i>Journal of Thoracic Disease</i> , 2011, 3, 144-6.	0.6	3
189	Evaluation of Tumor Position and PTV Margins Using Image Guidance and Respiratory Gating. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 76, 1578-1585.	0.4	24
190	Improving Radiation Conformality in the Treatment of Non-Small-Cell Lung Cancer. <i>Seminars in Radiation Oncology</i> , 2010, 20, 171-177.	1.0	64
191	Intensity-Modulated Proton Therapy Reduces the Dose to Normal Tissue Compared With Intensity-Modulated Radiation Therapy or Passive Scattering Proton Therapy and Enables Individualized Radical Radiotherapy for Extensive Stage IIIB Non-Small-Cell Lung Cancer: A Virtual Clinical Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 77, 357-366.	0.4	249
192	Stereotactic Body Radiation Therapy for Patients With Lung Cancer Previously Treated With Thoracic Radiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010, 78, 1387-1393.	0.4	151
193	Genetic Variants in Inflammation-Related Genes Are Associated with Radiation-Induced Toxicity Following Treatment for Non-Small Cell Lung Cancer. <i>PLoS ONE</i> , 2010, 5, e12402.	1.1	91
194	Cancer of the Lung. <i>Medical Radiology</i> , 2010, , 755-775.	0.0	0
195	Esophageal cancer: diagnosis and management. <i>Chinese Journal of Cancer</i> , 2010, 29, 843-854.	4.9	24
196	Determination of patient-specific internal gross tumor volumes for lung cancer using four-dimensional computed tomography. <i>Radiation Oncology</i> , 2009, 4, 4.	1.2	76
197	Consequences of Anatomic Changes and Respiratory Motion on Radiation Dose Distributions in Conformal Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009, 73, 94-102.	0.4	47
198	Stereotactic radiotherapy for lung cancer using a flattening filter free Clinac. <i>Journal of Applied Clinical Medical Physics</i> , 2009, 10, 14-21.	0.8	87

#	ARTICLE	IF	CITATIONS
199	Stereotactic Body Radiation Therapy in Centrally and Superiorly Located Stage I or Isolated Recurrent Non-small-Cell Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 967-971.	0.4	251
200	Effects of Interfractional Motion and Anatomic Changes on Proton Therapy Dose Distribution in Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008, 72, 1385-1395.	0.4	81
201	Treatment of Radioresistant Stem-Like Esophageal Cancer Cells by an Apoptotic Gene-Armed, Telomerase-Specific Oncolytic Adenovirus. <i>Clinical Cancer Research</i> , 2008, 14, 2813-2823.	3.2	96
202	Image-Guided Radiation Therapy for Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2008, 3, 177-186.	0.5	101
203	A technique for reducing patient setup uncertainties by aligning and verifying daily positioning of a moving tumor using implanted fiducials. <i>Journal of Applied Clinical Medical Physics</i> , 2008, 9, 110-122.	0.8	5
204	Stereotactic Body Radiation Therapy for Stage I Non-small Cell Lung Cancer. <i>Thoracic Surgery Clinics</i> , 2007, 17, 251-259.	0.4	36
205	PD4-1-6: Acute esophageal reactions from proton beam therapy and concurrent chemotherapy for non-small cell lung cancer (NSCLS): Reduction in incidence and severity despite higher doses. <i>Journal of Thoracic Oncology</i> , 2007, 2, S449.	0.5	8
206	4D Proton treatment planning strategy for mobile lung tumors. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 906-914.	0.4	178
207	Assessing Respiration-Induced Tumor Motion and Internal Target Volume Using Four-Dimensional Computed Tomography for Radiotherapy of Lung Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 531-540.	0.4	306
208	Assessment of Gross Tumor Volume Regression and Motion Changes During Radiotherapy for Non-small-Cell Lung Cancer as Measured by Four-Dimensional Computed Tomography. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1036-1046.	0.4	162
209	Comparison of Conformity Index In 3D-CRT, IMRT, and Proton Therapy in Lung Cancer: In Reply to Dr. Armstrong. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 68, 1272.	0.4	1
210	Intrathoracic Patterns of Failure for Non-small-Cell Lung Cancer With Positron-Emission Tomography/Computed Tomography-Defined Target Delineation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 69, 1409-1416.	0.4	36
211	Tumor-specific apoptotic gene targeting overcomes radiation resistance in esophageal adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 64, 1482-1494.	0.4	13
212	Significant reduction of normal tissue dose by proton radiotherapy compared with three-dimensional conformal or intensity-modulated radiation therapy in Stage I or Stage III non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 65, 1087-1096.	0.4	290
213	Promising clinical outcome of stereotactic body radiation therapy for patients with inoperable Stage I/II non-small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006, 66, 117-125.	0.4	285
214	The prevalence of myocardial ischemia after concurrent chemoradiation therapy as detected by gated myocardial perfusion imaging in patients with esophageal cancer. <i>Journal of Nuclear Medicine</i> , 2006, 47, 1756-62.	2.8	72
215	Surgical patterns of care in operable lung carcinoma treated with radiation. <i>Journal of Thoracic Oncology</i> , 2006, 1, 526-31.	0.5	0
216	Intensity modulated radiation therapy and proton radiotherapy for non-small cell lung cancer. <i>Current Oncology Reports</i> , 2005, 7, 255-259.	1.8	33

#	ARTICLE	IF	CITATIONS
217	Radiotherapy Sensitization by Tumor-Specific TRAIL Gene Targeting Improves Survival of Mice Bearing Human Nonâ€“Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2005, 11, 6657-6668.	3.2	39
218	High Mutagen Sensitivity in Peripheral Blood Lymphocytes Predicts Poor Overall and Disease-Specific Survival in Patients with Stage III Nonâ€“Small Cell Lung Cancer Treated with Radiotherapy and Chemotherapy. <i>Clinical Cancer Research</i> , 2005, 11, 2894-2898.	3.2	10
219	Feasibility of using intensity-modulated radiotherapy to improve lung sparing in treatment planning for distal esophageal cancer. <i>Radiotherapy and Oncology</i> , 2005, 77, 247-253.	0.3	150
220	Validation of an accelerated â€“demonsâ€“ algorithm for deformable image registration in radiation therapy. <i>Physics in Medicine and Biology</i> , 2005, 50, 2887-2905.	1.6	537
221	Telomerase: A potential molecular marker and therapeutic target for cancer. <i>Journal of Surgical Oncology</i> , 2004, 87, 1-3.	0.8	8
222	Dose and volume reduction for normal lung using intensity-modulated radiotherapy for advanced-stage nonâ€“small-cell lung cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004, 58, 1258-1267.	0.4	249